Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.
H. Jack West, MD
Advertisement
Articles by H. Jack West, MD
A panel of experts debate the cost of innovation vs disruptive pricing of therapy.
Advertisement
Latest Updated Articles
Dr. West on the Use of Nivolumab/Ipilimumab in Metastatic NSCLCPublished: January 14th 2021 | Updated:
Dr. West on Advancements for Patients With T790M-Mutant NSCLCPublished: August 8th 2016 | Updated:
Dr. West on FDA Approval of Brigatinib in ALK+ NSCLCPublished: May 2nd 2017 | Updated:
Dr. West on FDA Approval of Frontline Ceritinib for Frontline ALK+ NSCLCPublished: May 27th 2017 | Updated:
Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLCPublished: November 7th 2017 | Updated:
Dr. West on Lurbinectedin in SCLCPublished: September 20th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5